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Inhalation of BudesonideFormoterol
Increases Diaphragm Muscle
Contractility
Chiyohiko Shindoh1, Rie Shishido1, Natsu Narumi1, Naomi Murai1 and Masahito Miura1
ABSTRACT
Background: Although budesonideformoterol (BUDFORM) is used clinically as a steroidβ2-agonist single
inhaler, it has not yet been clarified whether BUDFORM has inotropic effects on diaphragm muscles after in-
halation.
Methods: We examined the effects of BUDFORM inhalation, endotoxin injection, and BUDFORM inhalation
plus endotoxin injection on diaphragm contractile properties and nitric oxide (NO) production. After these three
treatments, the diaphragm muscle was dissected, and its contractile properties were measured. Histochemistry
for the reduced form of nicotinamide adenine dinucleotide phosphate diaphorase was performed for each mus-
cle to assess NO production.
Results: The force-frequency curves showed an upward shift 1 h after inhalation (p < 0.05) in the BUDFORM
inhalation only group. The force-frequency curves showed a downward shift 4 h after injection (p < 0.001) in the
endotoxin injection groups. In the BUDFORM inhalation plus endotoxin injection groups, a downward shift in
the force-frequency curves at 4 h after endotoxin injection was prevented. NO production was inhibited in the
BUDFORM inhalation plus endotoxin injection group compared with that of the endotoxin injection only
groups.
Conclusions: BUDFORM inhalation has an inotropic effect on diaphragm muscle, protects diaphragm mus-
cle deterioration after endotoxin injection, and inhibits NO production. Increments in muscle contractility with
BUDFORM inhalation are induced through a synergistic effect of an anti-inflammatory agent and β2-agonist.
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ABBREVIATIONS
arbitrary unit, a.u.; BUDFORM, budesonideformoterol; CSA, cross-sectional area; CT, contraction time;
Esham, E1, E2, and E4, saline injection as a sham, and after 1, 2, and 4 h of endotoxin injection, respectively;
HRT, half relaxation time; ICS, inhaled corticosteroid; iNOS, inducible NO synthase; LABA, long-acting β2-
agonist; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, NADP, reduced form; NO, nitric oxide;
Ssham, S1, S2, and S4, sham inhalation with lactose, and after 1, 2, and 4 h of BUDFORM inhalation, respec-
tively; SEsham, SE1, SE2, and SE4, sham inhalation with lactose and saline injection, and after 1, 2, and 4 h of
BUDFORM inhalation and endotoxin injection, respectively; TNF-α, tumor necrosis factor-α; TT, twitch ten-
sion; TTCT, slope during contraction time; (TT2)HRT, slope during half relaxation time.
INTRODUCTION
Budesonideformoterol (BUDFORM) in a single in-
haler is used to treat patients with bronchial asthma.
In a study by Pauwels et al.,1 the greatest reduction in
exacerbation occurred in patients receiving both a
high dose of inhaled corticosteroid (ICS) and the ad-
dition of a long-acting β2-agonist (LABA). Single in-
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haler therapy with budesonide and formoterol is a
clinically effective and well-tolerated treatment for pa-
tients with asthma that is not fully controlled by in-
haled glucocorticosteroids alone. A previous study
found a greater increase in morning peak flow with a
single-inhaler (35.7 Lmin) and separate-inhaler (32.0
Lmin) of budesonide and formoterol compared with
budesonide alone.2 Cellular studies have shown that
both glucocorticoids and β2-agonists (10−8 molL) ac-
tivate CEBP-α and the glucocorticoid receptor with
different kinetic profiles and inhibit proliferation, and
the combination of lower drug doses (10−12 to 10−9
molL) results in a synchronized activation of tran-
scription factors and enhances the antiproliferative ef-
fect.3 Therefore, in patients with persistent asthma
symptoms despite treatment with inhaled glucocorti-
coids, the addition of formoterol to budesonide ther-
apy has been shown to improve symptoms and lung
function and may be beneficial.
Moreover, BUDFORM in a single inhaler is as
safe and effective in long-term (12 months) asthma
treatment as budesonide plus formoterol via separate
inhalers. A lower number of withdrawal symptoms in
patients using BUDFORM may reflect better adher-
ence to treatment compared with budesonide inhala-
tion and formoterol as a rescue inhalation.4 In addi-
tion, BUDFORM (80 μg4.5 μg, 2 inhalations b.i.d)
for both maintenance and relief improves asthma con-
trol with a lower steroid load compared with a higher
dose of budesonide (160 μg, 2 inhalations b.i.d) plus
terbutaline (0.4 mg) as needed.5 These reports have
shown the safety and compliancy of the BUDFORM
single inhaler in asthma treatment. However, it has
not yet been clarified whether BUDFORM has
inotropic effects on diaphragm muscles after inhala-
tion.
We have previously studied the effects of endo-
toxin injection on diaphragm muscle contractile prop-
erties and showed that endotoxin injection induces a
decrement in diaphragm muscle contractility.6 This
deterioration may be caused by a network of cytoki-
nes such as tumor necrosis factor-α (TNF-α)6 and
free radicals such as nitric oxide (NO) and oxygen
derived intermediates, including superoxide and the
hydroxyl radicals.7 Therefore, BUDFORM inhala-
tion is expected to confer a protective effect against
diaphragm muscle deterioration in contractile proper-
ties and NO production induced by endotoxin.
In the current study, we examined the effects of
BUDFORM inhalation and BUDFORM inhalation
plus endotoxin injection on diaphragm contractile
properties and NO production. We first investigated
the effects of BUDFORM only inhalation in normal
animals and measured diaphragm contractile proper-
ties for the following 4 h. We then assessed whether
BUDFORM inhalation and endotoxin injection have
protective effects against endotoxin-induced deterio-
ration of diaphragm muscle.
METHODS
ANIMAL PREPARATION
Experiments were performed on 60 mice divided into
three groups (n = 20 of animals for each group) using
BALBc mice weighing 24.2 ± 0.4 g (Charles River Ja-
pan, Tokyo, Japan). In the BUDFORM inhalation
only groups, animals inhaled BUDFORM (36 μg1
μg, a total of 200 μg with lactose) using a dry powder
insufflator (DP-4-M, Penn-Century, Wyndmoor, PA,
USA) with an air pump (200 μL of air, AP-1, Penn-
Century). The dose of BUD (36 μg) was calculated as
approximately 4% deposition (40 μg) in the lung of
1000 μg aerosol inhalation in mice.8 The concentra-
tion combination of BUDFORM (36 μg1 μg) was
approximately one-fourth that of a commercially avail-
able dry powder inhaler (BUDFORM [160 μg4.5
μg for one puff]; SymbicortⓇ), which was provided by
AstraZeneca (Lund, Sweden). Animals were lightly
anesthetized in a glass jar into which diethyl ether
drops were added. The animals were then removed
from the jar and perpendicularly fixed on a surgery
board with a face mask treated with diethyl ether. Im-
mediately after fixation, the epiglottis of the animal
was extended using a laryngoscope (LS-2 for mouse,
LMS, Tokyo, Japan), and dry powder was adminis-
tered through two puffs in front of the opening of the
vocal cords during spontaneous breathing. Dia-
phragm muscles were dissected and contractility was
measured immediately after sham inhalation with lac-
tose (200 μg) (Ssham), and after 1 (S1), 2 (S2) and
4 h (S4) of BUDFORM inhalation (n = 5 animals
each). In the endotoxin injection only groups, animals
were intraperitoneally injected with Escherichia coli
endotoxin (20 mgkg, 055: B5, Sigma Chemical, St.
Louis, MO, USA) in 0.5 mL of saline, and muscle con-
tractility was measured after saline (0.5 mL only) in-
jection as a sham experiment (Esham), and after 1
(E1), 2 (E2) and 4 h (E4) of endotoxin injection (n = 5
animals each). In the BUDFORM inhalation plus en-
dotoxin groups, animals initially inhaled BUDFORM
(361 μg) using a dry powder insufflator (DP-4-M,
Penn-Century) with an air pump (200 μL of air, AP-1,
Penn-Century), followed immediately by intraperito-
neal injection of E. coli endotoxin (20 mgkg) in 0.5
mL of saline. Diaphragm muscles were then dis-
sected, and muscle contractility was measured imme-
diately after sham inhalation with lactose (200 μg)
and saline injection (0.5 mL only) (SEsham), and af-
ter 1 (SE1), 2 (SE2) and 4 h (SE4) BUDFORM inha-
lation plus endotoxin injection (n = 5 animals each).
We have previously shown that the force-frequency
curves of diaphragm muscle maximally decreased at
3 to 4 h and then recovered at 6 h after endotoxin in-
jection.6 Therefore, we measured and analyzed dia-
phragm muscle contractility 4 h after endotoxin ad-
ministration. Written approval was obtained from the
Tohoku University Animal Facility.
BUDFORM Inhalation and Diaphragm Muscle
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MEASUREMENTS OF MUSCLE CONTRACTION
Muscle strips (width, 3 to 4 mm; length, 8 to 11 mm;
weight, 0.008 to 0.010 g) were dissected from the
right and left hemidiaphragm of each animal under
diethyl ether anesthesia and mounted in separate or-
gan baths containing Krebs-Henseleit solution oxy-
genated with a 95% O2 and 5% CO2 gas mixture (37.0
± 0.5℃, pH 7.40 ± 0.05). The composition of the aer-
ated Krebs-Henseleit solution in mEqL was as fol-
lows: Na+, 153.8; K+, 5.0; Ca2+, 5.0; Mg2+, 2.0; CL−,
145.0; HCO3−, 15.0; HPO42−, 1.9; SO42−, 2.0; glucose,
110 mg%; d-tubocurarine, 10 μM; and regular crystal-
line zinc insulin, 50 UL. Both muscle strips were si-
multaneously stimulated with supramaximal currents
of 200 to 250 mA (i.e., 1.2 to 1.5 times the current re-
quired to elicit maximal twitch tension and pulse du-
ration of 0.2 ms) by a constant current stimulus isola-
tion unit (SS-302J; Nihon Kohden, Tokyo, Japan)
driven by a stimulator (SEN-3201; Nihon Kohden).
The elicited tensions were measured using a force
transducer (UL-100GR; Minebea, Nagano, Japan)
The length of each muscle strip was altered by mov-
ing the position of the force transducer with a
micrometer-controlled rack and pinion gear (accu-
racy of displacement, 0.05 mm; Mitsutoyo, Aichi, Ja-
pan) and measured with a micrometer in close prox-
imity to the muscle. The optimal length (Lo) of the
muscle strip was defined as the muscle length at
which twitch tension development was maximal, and
this Lo was maintained in the following measure-
ments (isometric conditions). The cross-sectional
area (CSA) of the strip was calculated by dividing the
muscle mass by the product of the muscle strip
length (Lo) and muscle density (1.06 gcm3),9 or
CSA (cm2) = (muscle mass (g)1.06)Lo (cm). Ten-
sion (Ncm2) was calculated as force (N) per CSA
(cm2).
The diaphragm force-frequency relationship was
assessed by sequentially stimulating muscles at 1, 10,
20, 30, 50, 70, 100 and 120 Hz. Each stimulus train
was applied for approximately 1 s, and adjacent trains
were applied at approximately 10-s intervals. The ten-
sions of the muscle strips were recorded by a hot-pen
recorder (RECTI-HORIZ-8K; San-ei, Osaka, Japan).
The force-frequency curves of the groups are dis-
played as elicited tensions (Ncm2) versus stimula-
tion frequencies (Hz).
Twitch contraction was elicited by a single pulse
stimulation (0.2-ms pulse duration), and the twitch
contraction trace was recorded at high speed (10 cm
s). Twitch kinetics were assessed by twitch tension
(TT, Ncm2), contraction time (CT, the time required
to develop peak tension, ms) and half relaxation time
(HRT, the time required for peak tension to decrease
by 50%, ms) during a single muscle contraction. For
the analysis of contractile velocity of twitch contrac-
tions, TTCT (slope during contraction time) and
(TT2)HRT (slope during half relaxation time) were
calculated from the curve of the twitch contraction
trace.
Muscle fatigue was assessed by examining the rate
of tension decrease over a 5-min period of rhythmic
contraction, which was induced by applying trains of
20-Hz stimuli (train duration, 0.3 s; rest duration, 0.7
s) at a rate of 60 trainsmin. Muscle fatigue was ex-
pressed as a percentage of the final tension (%) com-
pared with initial tension. If this value was lower than
that at 0 h, we concluded that the muscle was easily
fatigued; however, if this value was higher than that
at 0 h, we concluded that the muscle was fatigue re-
sistant. Following this procedure, the muscle strip
was removed from the organ bath, the tendons and
attached fat tissues were removed, and the muscle
was weighed.
NICOTINAMIDE ADENINE DINUCLEOTIDE
PHOSPHATE (NADPH) DIAPHORASE HISTO-
CHEMISTRY
Twenty-seven BALBc mice weighing 23.7 ± 0.5 g
(Charles River Japan, Tokyo, Japan) were divided
into three groups for NADPH diaphorase histochemi-
cal analysis. NADPH diaphorase histochemistry of
diaphragm muscle was performed at 0, 1, 2, and 4 h
in the BUDFORM inhalation only group (n = 3 ani-
mals each), and at 0, 2, and 4 h of diaphragm muscle
in both the endotoxin injection only group (n = 3 ani-
mals each) and in the BUDFORM inhalation plus
endotoxin group (n = 3 animals each). The dia-
phragm was quickly excised, and the tissue pieces
were frozen in optimal cutting temperature com-
pound (OCT, Tissue-Tek, Sakura Finetechnical, To-
kyo, Japan) in a dry ice and acetone bath. Cryosec-
tions (10 μm in thickness) were cut from the dia-
phragm, and immersed in 0.3% Triton X-100 contain-
ing phosphate buffer for histochemistry. To test for
the presence of NADPH diaphorase, the sections
were dipped in freshly prepared 1.0 mM β-NADPH
(Oriental Yeast, Tokyo, Japan) and 0.2 mM nitroblue
tetrazolium (Wako Pharmaceutical, Osaka, Japan) in
100 mM Tris-HCL buffer pH 8.0, containing 0.2% Tri-
ton X-100 for 30 min at 37℃.10 Reactions were
stopped by rinsing the sections with PBS. The sec-
tions were covered with a mixture of glycerol and
PBS (2 : 1), and photographed using an Olympus mi-
croscope with positive color film (Velvia 100, Fuji-
chrome, Tokyo, Japan). Inducible NO synthase
(iNOS) requires NADPH as a coenzyme, which is
stained in a histochemical reaction for NADPH
diaphorase.11
We measured the mean density of the CSA of each
muscle fiber using software of image analyzer (NIH
Image, National Institute of Health, Bethesda, USA)
We counted more than 30 muscle fibers in each pho-
tograph. The densities were averaged and expressed
in arbitrary units (a.u.).
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Fig.　1　Changes in force-frequency curves in the BUD/
FORM inhalation only groups at Ssham (open circles), S1 
(open squares), S2 (open triangles) and S4 (closed circles). 
*p < 0.05 compared with each frequency (Hz) at Ssham; ＃p < 
0.05 compared with the force-frequency curve at Ssham.
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DATA ANALYSIS
Data were obtained from both halves of the dia-
phragm in each animal (n = 5 animals). Therefore,
the number of muscle samples used was n = 10 per
treatmenttime point for force-frequency curves,
twitch kinetics and fatigability. Mean values of ten-
sions for each frequency of force-frequency curves,
twitch kinetics, fatigability, and mean density of mus-
cle fibers were compared using the Student’s t-test.
To compare the entire configuration of each force-
frequency curve at each hour or concentration, analy-
sis of variance (ANOVA) with Fisher’s protected least
significant difference post hoc test were performed.
Data are presented as means ± SEM (standard error
of the mean). P values < 0.05 were considered to be
significant.
RESULTS
CHANGES IN CONTRACTION PROPERTIES IN
THE BUDFORM INHALATION ONLY GROUP
In the BUDFORM inhalation only group, the force-
frequency curve at S1 was significantly shifted up-
ward (15.5 ± 1.5 Ncm2 peak) compared with that at
Ssham (12.7 ± 0.4 Ncm2 peak, p < 0.05) (Fig. 1). The
force-frequency curve at S2 was shifted downward
(14.0 ± 0.6 Ncm2 peak) compared with that at S1,
and the force-frequency curve at S4 (13.5 ± 0.9 Ncm2
peak) was shifted between Ssham and S2. According
the changes of the force-frequency curve at S1, sig-
nificant changes in tension were also observed at 30,
50, 70, 100 and 120 Hz for S1 (each p < 0.05) com-
pared with those at Ssham (Fig. 1).
In the BUDFORM inhalation only groups, there
were no significant differences in TT, CT, and HRT of
twitch contraction and fatigability at each time point
compared with values at Ssham (Fig. 2). No signifi-
cant differences were observed in TTCT and (TT
2)HRT of twitch contraction (Fig. 3).
NADPH diaphorase histochemistry showed that in
the BUDFORM inhalation only group at S2 (92.8 ±
6.3 a.u.), there was a slight but non-significant in-
crease in mean density compared with the level at
Ssham (82.7 ± 5.1 a.u.), and the staining disappeared
at S4 (83.72 ± 6.6 a.u., Fig. 4). This slight increase in
staining at S2 in the BUDFORM inhalation only
group suggested that NO production may have been
induced by BUDFORM. However, this staining did
not correspond with the time course changes of dia-
phragm muscle contractility.
CHANGES IN CONTRACTION PROPERTIES IN
THE ENDOTOXIN ONLY AND BUDFORM INHA-
LATION PLUS ENDOTOXIN GROUPS
For the endotoxin injection only groups, the force-
frequency curves were significantly shifted down-
ward at E2 (9.6 ± 0.6 Ncm2 peak, p < 0.001) and at
E4 (6.9 ± 0.7 Ncm2 peak, p < 0.001) compared with
those at Esham (12.3 ± 0.6 Ncm2 peak) (Fig. 5A).
Significant decreases in tensions were observed at 10,
20, and 30 Hz (each p < 0.05) at E1, at 10, 20, 30, 50,
70, 100, and 120 Hz (each p < 0.05) at E2, and at 10 (p
< 0.01), 20 (p < 0.001), 30 (p < 0.01), 50, 70, 100, and
120 Hz (each p < 0.001) at E4 compared with Esham
(Fig. 5A). Therefore, low frequency fatigue (at 10, 20,
and 30 Hz) occurred at E1, and tensions of high fre-
quency (70 to 120 Hz) at E1 did not exhibit significant
changes. These changes indicated that the intraperi-
toneal administration of endotoxin deteriorated dia-
phragm muscle contraction in the 4 h follow-up pe-
riod. However, in the BUDFORM inhalation plus en-
dotoxin groups, the force-frequency curve was signifi-
cantly shifted upward at SE4 (14.9 ± 0.6 Ncm2 peak,
p < 0.05) compared with that at SEsham (12.7 ± 0.4
Ncm2 peak), and the force-frequency curve at SE4
(14.9 ± 0.6 Ncm2 peak, p < 0.01) was also signifi-
cantly shifted upward compared with that at SE1
(11.6 ± 0.7 Ncm2 peak) (Fig. 5B). Tensions of force-
frequency curves at SE4 showed significant increases
at 1 and 10 Hz (both p < 0.05) compared with those at
SEsham, and they were increased at 20, 30, 50, 70,
100, and 120 Hz (p < 0.05) compared with those at
SE1.
In the endotoxin injection only groups, TT of twitch
contraction was significantly decreased at E4 com-
pared with that at Esham (p < 0.01) and at E1 (p <
0.05) (Fig. 6A). However, there were no significant
changes in CT and HRT of twitch contraction and fati-
gability (Fig. 6B, C, D). In the BUDFORM inhala-
tion plus endotoxin groups, TT was significantly in-
BUDFORM Inhalation and Diaphragm Muscle
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Fig.　2　Changes in twitch kinetics in the BUD/FORM inhalation only groups at Ssham, S1, 
S2, and S4. There were no signifi cant changes in TT (A), CT (B), HRT (C) or fatigability (D). 
TT, twitch tension; CT, contraction time; HRT, half relaxation time.
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Fig.　3　Changes in twitch kinetics in the BUD/FORM inhalation only groups at Ssham, S1, 
S2, and S4. There were no signifi cant changes in TT/CT (A) and (TT/2)/HRT (B). TT, twitch 
tension; CT, contraction time; HRT, half relaxation time.
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creased at SE4 (p < 0.05) compared with that at SE-
sham (Fig. 6A); however, there were no significant
changes in CT, HRT and fatigability (Fig. 6B, C, D).
In the endotoxin injection only groups, TTCT of
twitch contraction was significantly decreased at E4
compared with that at Esham (p < 0.01) and at E1 (p <
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Fig.　4　NADPH diaphorase histochemistry in the BUD/FORM only inhalation groups. Histochemistry shows that those at 
S2 samples are slightly stained compared with staining at Ssham and then the staining becomes lighter at S4.
Ssham S2 S4
Fig.　5　(A) Changes in force-frequency curves in the endotoxin only injection groups at Esham (open circles), E1 (open 
squares), E2 (open triangles) and E4 (closed circles). *p < 0.05, **p < 0.01, ***p < 0.001 compared with each frequency at 
Esham; ＃＃＃p < 0.001 compared with the force-frequency curve at E4. (B) Changes in force-frequency curves in the BUD/
FORM inhalation plus endotoxin injection groups at SEsham (open circles), SE1 (open squares), SE2 (open triangles), and 
SE4 (closed circles). *p < 0.05 compared with each frequency at SEsham; †p < 0.05 compared with each frequency at SE1; 
＃p < 0.05, ＃＃p < 0.01 compared with the force-frequency curve at SEsham.
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0.05) (Fig. 7A). (TT2)HRT was significantly de-
creased at E4 compared with that at Esham (p < 0.01)
and at E1 (p < 0.001), and (TT2)HRT at E2 was also
significantly decreased compared with that at E1 (p <
0.05) (Fig. 7B). In the BUDFORM inhalation plus
endotoxin groups, (TT2)HRT at SE4 was signifi-
cantly increased (p < 0.05) compared with that at SE-
sham (Fig. 7B).
NADPH diaphorase histochemistry showed that
cross-sectional views of diaphragm muscle gradually
exhibited stronger staining from Esham (80.8 ± 4.3
a.u.) and E2 (126.9 ± 5.9 a.u., p < 0.01 compared with
Esham) to E4 (197.6 ± 2.4 a.u., p < 0.001 compared
with Esham) in the endotoxin injection only groups.
However, diaphragm muscle was not strongly stained
at SEsham (90.5 ± 5.7 a.u.), SE2 (85.6 ± 6.7 a.u.) and
SE4 (91.8 ± 5.1 a.u.) in the BUDFORM inhalation
plus endotoxin groups (Fig. 8). This increased stain-
ing at E4 indicated that NO production was strongly
induced by endotoxin injection. However, NO pro-
duction was depressed in the BUDFORM inhalation
and endotoxin groups for 4 h (from SEsham to SE4)
in muscle fibers of the diaphragm. These changes
corresponded well with the time course changes in
diaphragm muscle contractility both in the endotoxin
injection only and the BUDFORM inhalation plus
endotoxin groups. These data indicate that BUD
FORM protects against endotoxin-induced effects on
BUDFORM Inhalation and Diaphragm Muscle
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Fig.　6　Changes in twitch kinetics after endotoxin injection at Esham, E1, E2, and E4, and in the BUD/
FORM inhalation plus endotoxin groups at SEsham, SE1, SE2, and SE4 as measured by TT (A), CT (B), 
HRT (C), and fatigability (D). *p < 0.05, **p < 0.01 compared between two time points. TT, twitch tension; CT, 
contraction time; HRT, half relaxation time.
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diaphragm muscle contractility.
DISCUSSION
In the present study, the force-frequency curves of
the BUDFORM inhalation only groups were signifi-
cantly shifted upward at 1 h after inhalation, and then
returned to a value similar to Ssham in normal dia-
phragm muscle. Second, in the endotoxin injection
only groups, the force-frequency curves were signifi-
cantly shifted downward at E4 compared with that at
Esham; however, in the BUDFORM inhalation plus
endotoxin injection groups, the force-frequency
curves were significantly shifted upward at SE4, indi-
cating that BUDFORM inhalation can inhibit the de-
crease in force-frequency curves induced by endo-
toxin. Third, NO production induced by endotoxin at
E4 was inhibited by BUDFORM inhalation plus en-
dotoxin at SE4 according to NADPH diaphorase his-
tochemistry. Therefore, BUDFORM inhalation has
an inotropic effect on normal diaphragm muscle at
1 h and protects against both a decrease in force-
frequency curves and NO production of diaphragm
muscle induced by endotoxin.
There are some concerns regarding the dose of
BUDFORM and anesthesia in this study. As men-
tioned above in the Materials and Methods section,
the dose of BUDFORM (36 μg1 μg, total of 200 μg
with lactose) was calculated as approximately 4%
deposition (40 μg) in the lung of 1000 μg aerosol in-
halation in mice,8 and BUDFORM was approxi-
mately one-fourth that of a dry powder inhaler (BUD
FORM [160 μg4.5 μg for one puff]). We consider
that this inhalation study should be similar to clinical
use.
It has been reported that when 1000 μg of BUD
was inhaled in humans, blood concentrations of BUD
reached 4.8 nmolL (2.1 ngml) at 12.6 minutes after
inhalation.12 Therefore, the observed changes in
Shindoh C et al.
446 Allergology International Vol 61, No3, 2012 www.jsaweb.jp
Fig.　7　Changes in twitch kinetics in the endotoxin injection groups at Esham, E1, E2, and E4, and in the 
BUD/FORM inhalation plus endotoxin groups at SEsham, SE1, SE2, and SE4 as measured by TT/CT (A), and 
(TT/2)/HRT (B). *p < 0.05, **p < 0.01, ***p < 0.001 compared between two time points. TT, twitch tension; CT, 
contraction time; HRT, half relaxation time.
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Fig.　8　NADPH diaphorase histochemistry of the endotoxin injection only groups at Esham, E2, and E4, and of the BUD/
FORM inhalation plus endotoxin group at SEsham, SE2, and SE4. Histochemistry shows that cross-sectional views of dia-
phragm muscle are gradually more strongly stained from Esham and E2 to E4 in the endotoxin injection only groups. How-
ever, samples were not strongly stained from SEsham to SE4 in the BUD/FORM inhalation plus endotoxin groups.
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muscle contractile properties in our study are
thought to have been elicited by blood circulation of
BUDFORM after inhalation, which then reached
diaphragm muscle.
Anesthesia of diethyl ether is thought to have irrita-
tive, secretory and contractive effects on the airways,
and it might induce hypoxemia. In the current study,
we anesthetized mice in a jar in a short time of ap-
proximately 30 to 40 seconds while maintaining spon-
taneous breathing, and anesthesia was given in the
same manner in all animals. Therefore, we suggested
that the data obtained in our study could reflect the
effects of BUDFORM inhalation.
Pauwels et al. have published a pivotal report show-
BUDFORM Inhalation and Diaphragm Muscle
Allergology International Vol 61, No3, 2012 www.jsaweb.jp 447
ing that a combination of budesonide and formoterol
single inhalation in patients with persistent symptoms
of asthma despite treatment with inhaled glucocorti-
coids improves symptoms and lung function without
lowering asthma control.1 It has also been shown that
the addition of an inhaled LABA to an ICS may poten-
tiate the molecular mechanism of corticosteroid ac-
tion, with increased nuclear localization of glucocorti-
coid receptors and additive or sometimes synergistic
suppression of inflammatory mediator release.13 Fur-
thermore, clinical trials have recently shown that us-
ing a BUDFORM combination inhaler for regular
maintenance treatment twice daily and also for rescue
therapy for breakthrough symptoms can provide
more effective asthma control.14 As a rescue therapy,
formoterol is effective in relieving symptoms by relax-
ing airway smooth muscle, but it is also likely to have
important inhibitory effects on mast cells, plasma
exudation and neutrophilic inflammation. Therefore,
it is likely that molecular interactions between β2-
agonists and corticosteroids also enhance the effect
of the combination therapy as rescue therapy.
Our results suggest that BUDFORM inhalation
has an additive or a synergistic effect, such as an
inotropic effect on muscle contraction and an anti-
inflammatory effect on diaphragm muscle. We have
reported that β2-agonists, such as procaterol15 and tu-
lobuterol,16 shift force-frequency curves upward; this
inotropic effect may be caused by formoterol, which
is a β2-agonist. This inotropic effect by β2-agonists is
induced by β2 receptors in cell membranes and in-
creases cAMP.17 Additionally, an inhibitory effect on
NO production appears to be induced by budesonide,
which is transported into the cytoplasm, connects
with a steroid receptor, and is then transported to the
nucleus where it binds to DNA, which inhibits tran-
scription of iNOS and inflammatory cytokines. There-
fore, the combination of BUDFORM inhalation pro-
tects diaphragm muscle tissue and maintains contrac-
tile properties.
Inhibition of NO production by BUDFORM inha-
lation may indicate anti-inflammatory effects induced
by endotoxin injection in the diaphragm muscle tis-
sues. In vitro steroids down-regulate iNOS expres-
sion, thus suggesting a potential to down-regulate
NO-mediated inflammation in neonates with meco-
nium aspiration syndrome.18 In addition, allergen-
induced sputum eosinophilia is significantly reduced
by combination treatment to a greater extent than by
budesonide alone. The effects on allergen-induced
changes in sputum eosinophils, airway myofibroblast
numbers, and smooth muscle produced by combina-
tion therapy suggest that the beneficial effects on air-
way inflammation responses and airway hyperrespon-
siveness by combination treatment are likely due to
the known functional antagonistic effect of for-
moterol.19 Furthermore, budesonide and formoterol
combination therapy synergistically controls serum-
induced proteoglycan production, primarily at the
post-transcriptional level, and proteoglycan upregula-
tion characteristic of asthmatic airways may be lim-
ited by combination therapy with budesonide and for-
moterol.20
Furthermore, our results suggested that BUD
FORM inhalation plays a role in reducing asthma ex-
acerbation due to excessive breathing by preventing
diaphragm muscle deterioration. Rabe et al.21 found
that both monocomponents of budesonide-formoterol
given as needed contribute to enhanced protection
from severe exacerbations in patients receiving com-
bination therapy for maintenance. Although sympto-
matic control and rescue bronchodilator use may be
improved by the addition of a LABA to ICS, there
may be a lower risk of severe exacerbation and hospi-
talization from an ICS dose increase.22 However, ex-
acerbation and loss of asthma control in patients us-
ing combination therapy strongly suggest the need to
increase the ICS dose rather than relying on a long-
acting bronchodilator.23 Additionally, a previous
study found that there were very few asthma-related
deaths and intubations, and events were too infre-
quent to establish the relative effect of LABA on
these outcomes.24 Therefore, for many patients, the
addition of a LABA to ICS has been remarkably effec-
tive in improving symptom control, lung function, and
quality of life.
It has been reported that endotoxin administration
induces systemic effects. TNF-α plasma concentra-
tions are increased at 2 h after intravenous bolus in-
jection of E. colli endotoxin (0.3 ngkg) in humans,
and endotoxemia upregulates iNOS in the vascula-
ture.25 Our results showed that BUDFORM inhala-
tion improved diaphragm muscle contractility and de-
pressed NO production 4 h after endotoxin admini-
stration in the BUDFORM inhalation plus endotoxin
groups. Superoxide (O−.2 ) and NO are known to rap-
idly react to form a stable peroxynitrite anion, and su-
peroxide dismutase may protect vascular tissue
stimulated to produce superoxide and NO under
pathological conditions by preventing the formation
of peroxynitrite.26 We have previously reported that
N-acetylcysteine27 and PEG-superoxide dismutase28
have an anti-oxidant effect, preventing diaphragm
muscle deterioration induced by endotoxin. Further-
more, because TNF-α mRNA is expressed in dia-
phragm muscle cells after endotoxin administration,6
we also speculate that oxidative stress factors such as
TNF-α and NO may contribute to endotoxin-induced
diaphragm muscle contractile deterioration. There-
fore, the results of our experiments support the possi-
bility that BUDFORM inhalation inhibits oxidative
stress and induction of inflammatory cytokines such
as NO production and TNF-α. Recently, a national
survey of endotoxins in United States housing re-
ported that household endotoxin exposure is a signifi-
cant risk factor for increased asthma prevalence.29
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The most common risk factor in the development of
asthma is induction of IgE against indoor allergens
from pets containing endotoxin, which causes an im-
balance in T-helper type 1 and T-helper type 2 (Th2)
with skewing towards a Th2 response.30 Therefore,
endotoxin not only protects against the development
of asthma but also enhances an already established
inflammation. It may be important that BUDFORM
inhalation prevents airway inflammation and dia-
phragm deterioration when patients with bronchial
asthma have increased pulmonary and systemic oxi-
dative stress both at rest and under conditions of ex-
acerbation.
Before the availability of ICSs, patients with severe
asthma attacks were frequently treated with oral ster-
oids, and several studies have shown adverse effects
on muscular tissues. Afifi et al. reported a case of a
45-year-old housewife with a chronic asthmatic condi-
tion that had been treated with bronchodilators and a
steroid (methylprednisolone 12 mgday), causing
her to experience muscular weakness in her legs, in
which massive aggregates of glycogen in subsar-
colemmal and intermyofibrillar sites and disarray and
loss of myofibrils were observed.31 In a review of
short-term treatment with high doses of steroids,
generalized muscle, including respiratory muscles,
was found to be accompanied by reduced respiratory
muscle force.32 An ATPase stain for muscle fiber typ-
ing showed that diffuse fiber atrophy predominantly
affecting fast fibers was present, although there was
no indication that atrophy was confined to type IIb
(fast-twitch) fibers.33 Steroid administration (triamci-
nolone acetonide 1.2 mgkg per day) of 8 days pro-
duced diaphragmatic atrophy as severe as that of the
fast-twitch hindlimb muscle in an animal experi-
ment.34 In a small animal such as the rat, the percent-
ages of type I (slow-twitch) and type II are approxi-
mately 29% and 71%, respectively,35 and in humans,
these percentages are approximately 36% and 64%, re-
spectively.36 Our study was exerted only in the initial
4 hours after BUDFORM inhalation, and therefore,
the pathological changes mentioned above could be
avoided. Although there are some differences in the
composition of muscle fiber typing within mice and
humans, our results might be applicable to human
diaphragm contractile function as suggested by our
findings of BUDFORM inhalation.
Furthermore, it has been reported that steroids, at
doses typically administered in chronic severe
asthma (from 9 to 24 mgday), do not cause muscu-
lar weakness, and that malnutrition rather than corti-
costeroids is the most important contributory factor
to type II muscle fiber atrophy in steroid-dependent
asthma patients.37 Knowledge of the pharmacokinetic
properties of ICSs is important for the achievement of
high levels of airway selectivity. There should also be
an additional focus on the use of prodrugssoftdrugs
relative to those of conventional corticosteroid mole-
cules, and determining mechanisms (such as esterifi-
cation) by which retention at the target site is
achieved while minimizing systemic exposure and
the role of plasma protein binding.38 If the above-
mentioned effects on diaphragm muscle cannot be
avoided, they might be decreased by a small dosage
of inhalation (budosonide) and combination with a β2-
agonist (formoterol). β2-agonists have a direct
inotropic activity on diaphragm muscle contractility
by inhalation.15,16 Roth et al. have reported that the
concentration of inhaled glucocorticoids can be re-
duced when combined with β2 agonists, minimizing
the adverse effects of these drugs.3 Therefore, on the
basis of our results, we conclude that the combina-
tion of budosonide and formoterol is expected to im-
prove diaphragm muscle contractile weakness
caused by steroids.
In conclusion, BUDFORM inhalation has an
inotropic effect on diaphragm muscle, protects dia-
phragm muscle deterioration after endotoxin injec-
tion, and inhibits NO production. Although our study
performed endotoxin injection in an animal model, it
has been reported that inhaled endotoxin enhances
the response to allergen challenge in patients with
asthma, i.e., it enhances inflammatory responses.39
Therefore, BUDFORM inhalation may improve dia-
phragm muscle contractile properties in patients with
bronchial asthma by its inhibition of NO production,
and contribute to reduction of exacerbation in pa-
tients with bronchial asthma.
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